The Group's principal activity is to develop and commercialize oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, with two product candidates in clinical development. It's products are novel therapies that are designed to be safe, effective and convenient resulting in enhanced patient compliance. ALTU-242, is an orally-administered enzyme replacement therapy consisting of three digestive, enzymes, lipase, protease and amylase, for the treatment of malabsorption due to exocrine pancreatic insufficiency.
Alacra Alerts:
Receive alerts on the latest reports on Altus Pharmaceuticals Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
